Format

Send to

Choose Destination
Semin Nucl Med. 2015 Jan;45(1):58-65. doi: 10.1053/j.semnuclmed.2014.07.008.

Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Author information

1
PET/CT Imaging Science Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA. Electronic address: jadvar@med.usc.edu.
2
PET/CT Imaging Science Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Abstract

The use of (18)F-sodium fluoride ((18)F-NaF) with PET/CT is increasing. This resurgence of an old tracer has been fueled by several factors including superior diagnostic performance over standard (99m)Tc-based bone scintigraphy, growth in the availability of PET/CT imaging systems, increase in the number of regional commercial distribution centers for PET radiotracers, the recent concerns about potential recurring shortages with (99m)Tc-based radiotracers, and the recent decision by the Centers for Medicare and Medicaid Services to reimburse for (18)F-NaF PET/CT for evaluation of patients with known or suspected bone metastases through the National Oncologic PET Registry. The major goal of this article is to review the current evidence on the diagnostic utility of (18)F-NaF in the imaging assessment of the bone and joint in a variety of clinical conditions.

PMID:
25475379
PMCID:
PMC4258001
DOI:
10.1053/j.semnuclmed.2014.07.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center